Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTS9Q5V)

DTT Name	Sarcoglycan alpha (SGCA)
Synonyms	SGCA; Dystroglycan2; Alphasarcoglycan; AlphaSG; Adhalin; 50DAG; 50 kDa dystrophinassociated glycoprotein
Gene Name	SGCA
DTT Type	Clinical trial target	[1]
BioChemical Class	Sarcoglycan
UniProt ID	SGCA_HUMAN
TTD ID	T84584
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Sequence	MAETLFWTPLLVVLLAGLGDTEAQQTTLHPLVGRVFVHTLDHETFLSLPEHVAVPPAVHI TYHAHLQGHPDLPRWLRYTQRSPHHPGFLYGSATPEDRGLQVIEVTAYNRDSFDTTRQRL VLEIGDPEGPLLPYQAEFLVRSHDAEEVLPSTPASRFLSALGGLWEPGELQLLNVTSALD RGGRVPLPIEGRKEGVYIKVGSASPFSTCLKMVASPDSHARCAQGQPPLLSCYDTLAPHF RVDWCNVTLVDKSVPEPADEVPTPGDGILEHDPFFCPPTEAPDRDFLVDALVTLLVPLLV ALLLTLLLAYVMCCRREGRLKRDLATSDIQMVHHCTIHGNTEELRQMAASREVPRPLSTL PMFNVHTGERLPPRVDSAQVPLILDQH
Function	Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix.
KEGG Pathway	Hypertrophic cardiomyopathy (hsa05410 ) Arrhythmogenic right ventricular cardiomyopathy (hsa05412 ) Dilated cardiomyopathy (hsa05414 ) Viral myocarditis (hsa05416 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

2 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SRP-9004	DMK095Z	Limb girdle muscular dystrophy	8C70.4	Phase 1/2	[2]
rAAV1.tMCK.human-alpha-sarcoglycan	DM1N8PZ	Discovery agent	N.A.	Phase 1	[1]
------------------------------------------------------------------------------------

References

1	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
2	Clinical pipeline report, company report or official report of Sarepta Therapeutics.